Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

181. Pericyazine for schizophrenia. (PubMed)

Pericyazine for schizophrenia. Pericyazine is a 3-cyano-10 (3-4'-hydroxypiperidinopropyl) phenothiazine. It is overall pharmacologically similar with chlorpromazine, though particularly sedating. Dopamine receptor subtype analysis has not been performed for pericyazine, but the drug appears to induce greater noradrenergic than dopaminergic blockade. Compared to chlorpromazine, pericyazine reportedly has more potent antiemetic, antiserotonin, and anticholinergic activity.To evaluate the clinical (...) effects and safety of pericyazine in comparison with placebo, typical and atypical antipsychotic agents and standard care for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (February 2013) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials.All relevant randomised controlled trials focusing on pericyazine for schizophrenia and other types of schizophrenia-like psychoses

Full Text available with Trip Pro

2014 Cochrane

182. Carbamazepine for schizophrenia. (PubMed)

Carbamazepine for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication (...) is an effective treatment for the same illnesses.For the original version we searched The Cochrane Schizophrenia Group's Register of Trials (December 2001), The Cochrane Library (Issue 3, 2001), MEDLINE (1966-2001), EMBASE (1980-2001), Biological Abstracts (1980-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). For the most recent update we searched the Cochrane Schizophrenia Group's Register of Trials in July 2012. We also inspected references of all identified studies for further trials and contacted

2014 Cochrane

183. Smoking cessation in patients with schizophrenia

Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smoking cessation in patients with schizophrenia. Lansdale: HAYES, Inc.. Directory Publication. 2014 Authors' conclusions The purpose of smoking cessation therapies (...) is to decrease smoking and smoking-related morbidity and mortality in patients. Interventions for smoking cessation may be pharmacologic and/or psychosocial. This report focuses on smoking cessation therapies in patients with schizophrenia. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Schizophrenia; Smoking Cessation Language Published English Country of organisation United States English summary An English language summary is available

2014 Health Technology Assessment (HTA) Database.

184. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. (PubMed)

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs.We did (...) a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation

Full Text available with Trip Pro

2014 Lancet

185. Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. (PubMed)

Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. Observational evidence suggests that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middle-income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the effectiveness of a collaborative (...) community-based care intervention with standard facility-based care.We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 and Dec 31, 2010. Patients aged 16-60 years with a primary diagnosis of schizophrenia according to the tenth edition of the International Classification of Diseases, Diagnostic Criteria for Research (ICD-10-DCR) were randomly assigned (2:1), via a computer-generated randomisation list with block sizes of three, six, or nine

Full Text available with Trip Pro

2014 Lancet

186. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. (PubMed)

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed

2014 Cochrane

187. Family intervention (brief) for schizophrenia. (PubMed)

Family intervention (brief) for schizophrenia. Supportive, positive family environments have been shown to improve outcomes for patients with schizophrenia in contrast with family environments that express high levels of criticism, hostility, or over-involvement, which have poorer outcomes and have more frequent relapses. Forms of psychosocial intervention, designed to promote positive environments and reduce these levels of expressed emotions within families, are now widely used.To assess (...) the effects of brief family interventions for people with schizophrenia or schizophrenia-like conditions.We searched the Cochrane Schizophrenia Group Trials Register (July 2012), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted authors of trials for additional information.All relevant randomised studies that compared brief family-oriented psychosocial interventions with standard care, focusing

Full Text available with Trip Pro

2014 Cochrane

188. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have (...) -effectiveness of lurasidone, compared with aripiprazole, for treating adult patients with schizophrenia, who had failed to respond to generic atypical antipsychotics. The authors concluded that lurasidone was less costly and more effective than aripiprazole. The results and modelling were well reported, but given the uncertainty around the use of all the best evidence available, the authors' conclusions may need to be interpreted with caution. Type of economic evaluation Cost-effectiveness analysis Study

2014 NHS Economic Evaluation Database.

189. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia

Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, Zilbershtein R, Jensen RC, Hemels ME, Einarson TR Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of long-acting injectable paliperidone palmitate for people with stable chronic schizophrenia and a history of relapse and hospitalisation. The authors concluded that paliperidone was the most cost-effective long-acting injectable atypical

Full Text available with Trip Pro

2014 NHS Economic Evaluation Database.

190. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. (PubMed)

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs.We did (...) a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation

Full Text available with Trip Pro

2014 Lancet

191. Perazine for schizophrenia. (PubMed)

Perazine for schizophrenia. Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia and is reputed to have a low level of extrapyramidal adverse effects. As far as we are aware, its use is limited to Germany, Poland, the former Yugoslavia and the Netherlands.To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications.We searched the Cochrane Schizophrenia (...) for people with schizophrenia or schizophrenia-like psychoses, or both.The review authors (SL, BH, BHe) independently inspected the citations and where possible abstracts and ordered papers for re-inspection and quality assessment. We independently extracted data. We calculated the risk ratio (RR) and 95% confidence interval (CI) using a random-effects model. For continuous data, we calculated mean differences (MD). We inspected all data for heterogeneity, assessed trials for risk of bias and created

Full Text available with Trip Pro

2014 Cochrane

192. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. (PubMed)

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. It is estimated that more than half of those with serious mental illness smoke tobacco regularly. Standard courses of pharmacotherapeutic cessation aids improve short-term abstinence, but most who attain abstinence relapse rapidly after discontinuation of pharmacotherapy.To determine whether smokers diagnosed with schizophrenia and bipolar disease have (...) higher rates of prolonged tobacco abstinence with maintenance pharmacotherapy than with standard treatment.Randomized, double-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 community mental-health centers. Of 247 smokers with schizophrenia or bipolar disease recruited from March 2008-April 2012, 203 received 12-weeks' open-label varenicline and cognitive behavioral therapy and 87 met abstinence criteria to enter the relapse prevention

Full Text available with Trip Pro

2014 JAMA

193. Chlorpromazine versus placebo for schizophrenia. (PubMed)

Chlorpromazine versus placebo for schizophrenia. Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia.To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information.We (...) included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non-affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care.We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95

2014 Cochrane

194. Social Skills Training for Schizophrenia

Social Skills Training for Schizophrenia Social Skills Training (SST) for Schizophrenia – Society of Clinical Psychology Description SST uses the principles of behavior therapy to teach communication skills, assertiveness skills, and other skills related to disease management and independent living. SST is usually conducted in small groups that are ideally led by two co-therapists. Skills are broken down into several discrete steps. After reviewing the steps of the skill, the therapist models (...) helpful when supplemented with community-based practice opportunities and support. Key References (in reverse chronological order) Kopelowicz, A., Liberman, R.P., Zarate, R. (2006) Recent advances in social skills training for schizophrenia. Schizophrenia Bulletin, 32, pS12-S23. Bellack, AS (2002). Skills training for people with severe mental illness. Psychiatric Rehabilitation, 7, 375-391 Glynn, S.M., Marder, S.R., Liberman, R.P, Blair, K., Wirshing, W.C., Wirshing, D.A., Ross, D., & Mintz, J. (2002

2014 Society of Clinical Psychology

195. Supported Employment for Schizophrenia

Supported Employment for Schizophrenia Supported Employment for Schizophrenia – Society of Clinical Psychology Description Supported Employment (SE; also known as Individual Placement and Support) is an approach to vocational rehabilitation (VR) adapted for individuals with serious mental illness. Supported employment emphasizes the integration of employment and mental health services, rapid placement of individuals into jobs in the community, individualized job development, and ongoing job (...) supports. Rather than segregating vocational rehabilitation and mental health services, supported employment specialists are part of the client’s treatment team. The goal of supported employment is to assist the person with schizophrenia in attaining competitive, community-based employment. As compared to more traditional VR approaches for this population (e.g. clubhouse models, transitional employment), the community-based nature of SE facilitates transfer of skills into real-world work settings

2014 Society of Clinical Psychology

196. Cognitive Adaptation Training for Schizophrenia

Cognitive Adaptation Training for Schizophrenia Cognitive Adaptation Training (CAT) for Schizophrenia – Society of Clinical Psychology Description Cognitive Adaptation Training (CAT) is designed to improve everyday functioning by teaching the individual with schizophrenia to use strategies that compensate for (or work around) the cognitive deficits associated with schizophrenia. Treatment plans are based on an assessment of the individual’s 1) level of apathy versus disinhibition and 2) level (...) and/or workplace. Key References (in reverse chronological order) Velligan , DI, Bow-Thomas, C.C., Huntzinger, C., Ledbetter, N., Prihoda, T.J., & Miller, A.L. (2000). Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. American Journal of Psychiatry, 157(8), 1317-1323. Velligan, D.I., Prihoda, T.J., Ritch, J.L., Maples, N., Bow-Thomas, C.C. & Dassori, A. (2002). A randomized single-blind pilot study of compensatory strategies

2014 Society of Clinical Psychology

197. Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism

Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Article Text Causes and risk factors Among untreated

2014 Evidence-Based Mental Health

198. Schizophrenia: lurasidone

Schizophrenia: lurasidone Schizophrenia: lur Schizophrenia: lurasidone asidone Evidence summary Published: 23 September 2014 nice.org.uk/guidance/esnm48 pathways This advice replaces ESNM15. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Lurasidone (Latuda, Sunovion (...) Pharmaceuticals Europe Ltd) is licensed for treating schizophrenia in adults aged 18 years and over. It was launched in the UK in August 2014. Evidence from 5 short- term and 3 long-term studies suggests that lurasidone is effective at treating psychotic symptoms, and at preventing relapse in adults with schizophrenia. The European Public Assessment Report [EPAR] for lurasidone states that the adverse event profile of lurasidone is similar to that for other second-generation antipsychotics, the most common

2014 National Institute for Health and Clinical Excellence - Advice

199. Psychosis and schizophrenia in adults: prevention and management

Psychosis and schizophrenia in adults: prevention and management Psy Psychosis and schizophrenia in adults: chosis and schizophrenia in adults: pre prev vention and management ention and management Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in adults: prevention and management (CG178) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

200. Schizophrenia: aripiprazole prolonged-release suspension for injection

Schizophrenia: aripiprazole prolonged-release suspension for injection Schizophrenia: aripipr Schizophrenia: aripiprazole prolonged-release azole prolonged-release suspension for injection suspension for injection Evidence summary Published: 26 March 2014 nice.org.uk/guidance/esnm39 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (...) (BNF) or the MHRA or NICE websites for up-to-date information. Summary Aripiprazole prolonged-release suspension for injection is licensed for maintenance treatment of schizophrenia in adults whose condition has been stabilised with oral aripiprazole. It was launched in the UK in January 2014. In 2 double-blind, randomised controlled trials (RCTs; n=403 and n=662), once-monthly aripiprazole 400 mg prolonged-release injection was shown to be superior to placebo and non-inferior to oral aripiprazole

2014 National Institute for Health and Clinical Excellence - Advice